As with any new medication, I suggest you have a discussion with your AME prior to starting the medication
From Figures 3, 4, it is quite clear that there is a cluster of three charged residues, i.e., Arg123 (L23B R in Figure 2, B Leu 32 in 4ZGM [29, 52]) of semaglutides backbone, Arg127 (Arg36 in Figure 1, B ARG 36 in 4ZGM [29, 52]) of semaglutides backbone and Glu40 of GLP-1R ECD (A GLU 68 in 4ZGM [29, 52]), sitting at the binding interface of the semaglutide-GLP-1R complex structure (Figure 3 and 4)
EnhancedVolcano: Publication-ready volcano plots with enhanced colouring and labeling
2 (download XLSX Raw and statistical source data
Research published in the Journal of Clinical Endocrinology and Metabolism found that GLP-1 receptor agonists and tirzepatide delay gastric emptying in a dose-dependent manner, with the most pronounced effects occurring after the initial dose